Why Pfizer Stock Was a Winner on Monday
The success of drug developers hinges on regulatory approvals for their medications. Considering that, it was hardly surprising that (NYSE: PFE) stock had a good Monday on the market. Following its latest Food and Drug Administration (FDA) nod, the company's shares closed the day 1.6% higher, topping the S 500 index's 0.5% rise.
That morning, Pfizer divulged that the FDA approved Padcev, the cancer drug developed with Japan's Astellas Pharma, to treat bladder cancer. Padcev has won the nod as part of a first-line combination therapy with Keytruda, Merck's blockbuster cancer drug.
The FDA's approval is based on the results of a phase 3 clinical trial of the two drugs used in combination. These demonstrated that taken together, the pair lowered the risk of death by 53% in patients with previously untreated bladder cancer, when compared to traditional chemotherapy.
Source Fool.com
Pfizer Inc. Aktie
Eine Tendenz zu Buy-Einschätzungen bei Pfizer Inc., überwiegend gegenüber Sell-Einschätzungen.
Für Pfizer Inc. sieht die Community ein Kursziel von 29 €, was eine erhebliche Steigerung um über 20% gegenüber dem aktuellen Kurs von 22.03 € bedeutet.
